Evidence map›Paper›PMID 30208034›Full record

ArticlePLoS neglected tropical diseases2018

Isometamidium chloride and homidium chloride fail to cure mice infected with Ethiopian Trypanosoma evansi type A and B.

Gebrekrustos Mekonnen, Elmi Fahiye Mohammed, Weldu Kidane, Awol Nesibu, Hagos Yohannes, Nick Van Reet, Philippe Büscher, Hadush Birhanu

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Vector-borne diseases-knowledge maps.EFSA journal. European Food Safety Authority · 2026
    Article
  3. Review
  4. Review
  5. Veterinary world · 2025
    Article
  6. Article
  7. Efficacy of diminazene diaceturate and isometamidium chloride hydrochloride for the treatment ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021
    Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Gebrekrustos MekonnenCollege of Veterinary Medicine, Mekelle University, Mekelle, Ethiopia.
Elmi Fahiye MohammedCollege of Veterinary Medicine, Mekelle University, Mekelle, Ethiopia.
Weldu KidaneCollege of Veterinary Medicine, Mekelle University, Mekelle, Ethiopia.
Awol NesibuSchool of Veterinary Medicine, Wollo University, Dessie, Ethiopia.
Hagos YohannesCollege of Veterinary Medicine, Mekelle University, Mekelle, Ethiopia.
Nick Van ReetInstitute of Tropical Medicine, Nationalesstraat 155, 2000 Antwerp, Belgium.
Philippe BüscherInstitute of Tropical Medicine, Nationalesstraat 155, 2000 Antwerp, Belgium.
Hadush BirhanuCollege of Veterinary Medicine, Mekelle University, Mekelle, Ethiopia.ORCID 0000-0003-3614-595X
Mekelle University · ETInstituut voor Tropische Geneeskunde · BESamara University · ETWollo University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTrypanosoma evansi is mechanically transmitted by biting flies and affects camels, equines, and other domestic and wild animals in which it causes a disease called surra. At least two types of Trypanosoma evansi circulate in Ethiopia: type A, which is present in Africa, Latin America and Asia, and type B, which is prevalent in Eastern Africa. Currently, no information is available about the drug sensitivity of any Ethiopian T. evansi type. METHODOLOGY/PRINCIPAL

findingsThis study was conducted with the objective of determining the in vivo drug sensitivity of two T. evansi type A and two type B stocks that were isolated from camels from the Tigray and Afar regions of Northern Ethiopia. We investigated the efficacy of four trypanocidal drugs to cure T. evansi infected mice: melarsamine hydrochloride (Cymelarsan), diminazene diaceturate (Veriben and Sequzene), isometamidium chloride (Veridium) and homidium chloride (Bovidium). Per experimental group, 6 mice were inoculated intraperitoneally with trypanosomes, treated at first peak parasitemia by daily drug injections for 4 consecutive days and followed-up for 60 days. Cymelarsan at 2 mg/kg and Veriben at 20 mg/kg cured all mice infected with any T. evansi stock, while Sequzene at 20 mg/kg caused relapses in all T. evansi stocks. In contrast, Veridium and Bovidium at 1 mg/kg failed to cure any T. evansi infection in mice. CONCLUSIONS/SIGNIFICANCE: We conclude that mice infected with Ethiopian T. evansi can be cured with Cymelarsan and Veriben regardless of T. evansi type. In contrast, Veridium and Bovidium are not efficacious to cure any T. evansi type. Although innate resistance to phenanthridines was previously described for T. evansi type A, this report is the first study to show that this phenomenom also occurs in T. evansi type B infections.

Indexed as

AnimalsArsenicalsDiminazeneDisease Models, AnimalEthiopiaFemaleInjectionsMicePhenanthridinesRecurrenceTreatment OutcomeTrypanocidal AgentsTrypanosomaTrypanosomiasisArsenicalsDiminazenediminazene aceturatehomidium chlorideisometamidium chloridemelaminylthioarsenatePhenanthridinesTrypanocidal Agents

Identifiers

PMID30208034
PMCPMC6152993
OpenAlexW2890548580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.